Effects of Remote Ischemic Preconditioning With Postconditioning on Neurologic Outcome
Not Applicable
Completed
- Conditions
- Remote Ischemic PreconditioningMoyamoya Disease
- Registration Number
- NCT03072914
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
In the present study, we evaluated whether RIPC with RIPostC reduce the major neurocomplication in patients undergoing STA-MCA anastomosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 108
Inclusion Criteria
- American Society of Anesthesiologists
- Adults 18 to 65 years of age
- In patients with planned MCA-STA anastomosis under general anesthesia
- Patients who pre-agreed to the study
Exclusion Criteria
- If there is a history of peripheral vascular arterial or venous disease
- If there is a previous history of peripheral nerve disease
- Other brain or cerebrovascular disease
- In case of serious cardiovascular disease, pulmonary disease, kidney disease
- Patients who do not agree with the test
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of major adverse event postoperative one month hyperperfusion syndrome, hypoperfusion, EDH, SAH, acute infarction
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie RIPC with RIPostC in Moyamoya Disease patients undergoing STA-MCA anastomosis?
How does RIPC with RIPostC compare to standard-of-care neuroprotective strategies in cerebral revascularization procedures?
Which biomarkers correlate with improved neurologic outcomes following RIPC with RIPostC in Moyamoya Disease?
What are the potential adverse events associated with RIPC with RIPostC during STA-MCA anastomosis and how are they managed?
Are there combination therapies or alternative ischemic conditioning protocols that enhance neuroprotection in Moyamoya Disease compared to RIPC with RIPostC?
Trial Locations
- Locations (1)
Seoul National Univ. Bundang Hospita
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Seoul National Univ. Bundang Hospita🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of